New York Life Investment Management LLC Sells 2,338 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

New York Life Investment Management LLC lowered its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLLFree Report) by 13.6% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,841 shares of the specialty pharmaceutical company’s stock after selling 2,338 shares during the period. New York Life Investment Management LLC’s holdings in Collegium Pharmaceutical were worth $332,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC grew its stake in shares of Collegium Pharmaceutical by 7.0% in the 2nd quarter. Los Angeles Capital Management LLC now owns 76,291 shares of the specialty pharmaceutical company’s stock worth $1,639,000 after buying an additional 5,023 shares during the last quarter. Illinois Municipal Retirement Fund purchased a new stake in Collegium Pharmaceutical during the 3rd quarter valued at $435,000. Allspring Global Investments Holdings LLC boosted its stake in Collegium Pharmaceutical by 1,019.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,670 shares of the specialty pharmaceutical company’s stock valued at $931,000 after purchasing an additional 37,946 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Collegium Pharmaceutical by 2.1% during the 2nd quarter. Principal Financial Group Inc. now owns 1,583,293 shares of the specialty pharmaceutical company’s stock valued at $34,025,000 after purchasing an additional 32,255 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Collegium Pharmaceutical by 10.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 39,105 shares of the specialty pharmaceutical company’s stock valued at $840,000 after purchasing an additional 3,558 shares during the last quarter.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 25,600 shares of the firm’s stock in a transaction on Monday, November 27th. The stock was sold at an average price of $25.78, for a total value of $659,968.00. Following the transaction, the executive vice president now directly owns 119,518 shares of the company’s stock, valued at approximately $3,081,174.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Shirley R. Kuhlmann sold 25,600 shares of the firm’s stock in a transaction on Monday, November 27th. The stock was sold at an average price of $25.78, for a total value of $659,968.00. Following the transaction, the executive vice president now directly owns 119,518 shares of the company’s stock, valued at approximately $3,081,174.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Scott Dreyer sold 23,560 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $32.28, for a total value of $760,516.80. Following the completion of the transaction, the executive vice president now directly owns 111,322 shares in the company, valued at $3,593,474.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,033 shares of company stock valued at $1,988,766. 3.69% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have commented on COLL shares. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 4th. Jefferies Financial Group reiterated a “hold” rating and set a $37.00 target price (up from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Truist Financial increased their price target on Collegium Pharmaceutical from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, January 4th. Finally, Needham & Company LLC reissued a “buy” rating and set a $40.00 price target on shares of Collegium Pharmaceutical in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.25.

Check Out Our Latest Research Report on COLL

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $33.70 on Tuesday. The business’s fifty day moving average price is $31.28 and its 200-day moving average price is $26.13. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of 224.67 and a beta of 1.01. The company has a debt-to-equity ratio of 2.95, a current ratio of 1.16 and a quick ratio of 1.08. Collegium Pharmaceutical, Inc. has a 1-year low of $20.83 and a 1-year high of $34.96.

Collegium Pharmaceutical Profile

(Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

See Also

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLLFree Report).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.